

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 March 2023 (02.03.2023)



(10) International Publication Number
WO 2023/028511 A1

(51) International Patent Classification:

A61K 47/65 (2017.01) *C07K 16/28* (2006.01)
A61K 47/68 (2017.01) *C12N 15/117* (2010.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/075381

(22) International Filing Date:

24 August 2022 (24.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/236,989 25 August 2021 (25.08.2021) US
63/256,270 15 October 2021 (15.10.2021) US

(71) Applicant: **TALLAC THERAPEUTICS, INC.** [US/US];
866 Malcolm Road, Suite 100, Burlingame, California
94010 (US).


(72) Inventors: **LI, Min**; c/o Tallac Therapeutics, Inc., 866 Mal-
colm Road, Suite 100, Burlingame, California 94010 (US).
HARRABI, Ons; c/o Tallac Therapeutics, Inc., 866 Mal-
colm Road, Suite 100, Burlingame, California 94010 (US).
CHEN, Amy; c/o Tallac Therapeutics, Inc., 866 Malcolm

Road, Suite 100, Burlingame, California 94010 (US). **SAN-
GALANG, Emma Ruth**; c/o Tallac Therapeutics, Inc., 866
Malcolm Road, Suite 100, Burlingame, California 94010
(US). **KUO, Tracy Chia-Chien**; c/o Tallac Therapeutics,
Inc., 866 Malcolm Road, Suite 100, Burlingame, Califor-
nia 94010 (US). **SIM, Bang Janet**; c/o Tallac Therapeu-
tics, Inc., 866 Malcolm Road, Suite 100, Burlingame, Cal-
ifornia 94010 (US). **WAN, Hong I.**; c/o Tallac Therapeu-
tics, Inc., 866 Malcolm Road, Suite 100, Burlingame, Cali-
fornia 94010 (US). **PONS, Jaume**; c/o Tallac Therapeutics,
Inc., 866 Malcolm Road, Suite 100, Burlingame, California
94010 (US).

(74) Agent: **JONES, Kevin** et al.; Morrison & Foerster LLP,
425 Market Street, San Francisco, California 94105-2482
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: SIRP-ALPHA ANTIBODIES AND CONJUGATES



Antibody: anti-SIRP- α

- Targets myeloid cells expressing SIRP α
- Localizes to tumor microenvironment of SIRP- α^+ tumors
- Engages Fc gamma receptors
- Blocks CD47-SIRP myeloid checkpoint pathway

Immune Activator: T-CpG

- Potent TLR9 agonist
- Linear, monomeric, and non-aggregated
- Sequence optimized for potency and stability
- Innovative design enables efficient site-specific conjugation

FIG. 17A

(57) Abstract: The present disclosure provides anti-SIRP- α polypeptide antibodies and oligonucleotide conjugates thereof. Also provided are related methods of preparation thereof and methods of use thereof, including therapeutic uses.

[Continued on next page]

WO 2023/028511 A1

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*